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EXPERIMENTAL STUDY
Carvedilol Increases the Production of Interleukin-12
and Interferon- and Improves the Survival of Mice
Infected With the Encephalomyocarditis Virus
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Akira Matsumori, MD, PHD, FACC
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OBJECTIVES This study was designed to examine the effects of carvedilol in a murine model of viral
myocarditis induced by encephalomyocarditis virus (EMCV) infection.
BACKGROUND Cytokines play an important role in the pathophysiology of viral myocarditis. Catecholamines
influence the production of cytokines via -adrenergic receptors, suggesting that -adrenergic
blockers could modulate the production of cytokines and exert a therapeutic effect in viral
myocarditis by blocking the -stimulating action of endogenous catecholamines. In clinical
trials, the third-generation, nonselective -blocker carvedilol was the first among several
-blockers to reduce mortality in heart failure. However, the effects of carvedilol in acute viral
myocarditis and on cytokine production are unknown.
METHODS This study compared the effects of carvedilol, the selective 1-blocker metoprolol, and the
nonselective -blocker propranolol in a murine model of viral myocarditis induced by
EMCV.
RESULTS Carvedilol improved the 14-day survival of the animals, attenuated myocardial lesions on day
7, and increased myocardial levels of interleukin (IL)-12 and interferon (IFN)-, whereas
reducing myocardial virus replication. Propranolol also attenuated myocardial lesions, but to
a lesser extent, and increased IL-12 and IFN- levels. Metoprolol had no effect in this model.
Encephalomyocarditis virus infection increased plasma catecholamine levels.
CONCLUSIONS These results suggest that by blocking the 2-stimulating effects of catecholamines, carvedilol
exerts some of its beneficial effects by increasing the production of IL-12 and IFN-.
Carvedilol may be effective in patients with viral myocarditis by boosting IL-12 and IFN-
production. (J Am Coll Cardiol 2003;41:340–5) © 2003 by the American College of
Cardiology Foundation
Viral infection of the myocardium produces an intense
inflammation, which can cause acute heart failure in hu-
mans and animals. Encephalomyocarditis virus (EMCV)
infection in DBA/2 mice causes acute myocarditis (1,2) and
induces several types of cytokines (3), as well as neuroen-
docrine hormones. Recent reports have emphasized the
importance of cytokines in the pathophysiology of viral
myocarditis (3–5). The roles of individual cytokines have
also been studied. The administration of interleukin (IL)-12
(4) or interferon (IFN)- (5) markedly improved survival,
attenuated myocardial lesions, and reduced myocardial viral
replication in this EMCV-induced myocarditis model.
In recent years, it has become clear that neuroendocrine
hormones participate in the cytokine network. Cat-
echolamines and several adrenergic agonists influence the
production of cytokines via -adrenergic receptors, which
increase intracellular cyclic adenosine monophosphate levels
(6–8). Therefore, we hypothesized that, when administered
in our model, -adrenergic antagonism may block the
effects of sympathetic stimulation on the production of
cytokines and modulate their production.
Beta-adrenergic blockers are now on the forefront in the
treatment of chronic heart failure (9–12). Carvedilol is a
vasodilating, nonselective -blocker with antioxidant prop-
erties (9,13,14). In large clinical trials, carvedilol reduced the
risk of death in chronic heart failure and offered a high
degree of cardiac protection in humans (9). However, its
effects in viral myocarditis and on cytokine production are
unknown. These experiments were performed to compare
the effects of carvedilol, the selective 1-blocker metoprolol,
and the nonselective -blocker propranolol in a murine
model of viral myocarditis induced by EMCV infection.
METHODS
Pharmaceuticals. Carvedilol was synthesized by Daiichi
Pharmaceutical Co., Ltd. (Tokyo, Japan). Metoprolol and
propranolol were synthesized by Sigma Chemical Company
(St. Louis, Missouri). They were mixed in phosphate-
buffered saline containing 1% methylcellulose.
Experimental infection. Four-week-old inbred male
DBA/2 mice were inoculated intraperitoneally with 0.1 ml
of the M variant of EMCV diluted in Eagle’s modified
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essential medium (Nissui Pharmaceutical Co., Tokyo, Ja-
pan) to a concentration of 100 plaque-forming units (pfu)/
ml. The day of virus inoculation was defined as day 0.
Measurement of plasma epinephrine and norepinephrine
levels. Blood was sampled from the animals’ tails. Plasma
was collected from uninfected control mice and infected
mice on day 7 (n  5 in each). The plasma specimens were
stored at 80°C until measurement of epinephrine or
norepinephrine levels by radioenzymatic assay, as described
previously (15).
Treatment protocols. PROTOCOL 1: DOSE-RELATED EF-
FECTS OF CARVEDILOL. Carvedilol was administered in a
dose of 3 or 10 mg/kg per day for 7 or 14 consecutive days,
whereas control mice received the vehicle only.
PROTOCOL 2: COMPARISON OF THE EFFECTS OF CARVE-
DILOL VERSUS METOPROLOL AND PROPRANOLOL. Carve-
dilol was administered in a dose of 10 mg/kg per day, and
metoprolol or propranolol was administered in a dose of 30
mg/kg per day for 7 or 14 consecutive days, whereas control
mice received the vehicle only. The 1-blocking effect in the
metoprolol or propranolol group was nearly equal to that in
the carvedilol group, whereas the 2-blocking effect in the
propranolol group was about three times larger than that in
the carvedilol group (16,17).
All drugs were administered orally once daily for 7 or 14
consecutive days, starting on day 0.
Survival experiments. Survival was measured over a 14-
day period.
Histologic examination. The hearts were fixed in 10%
formalin, embedded in paraffin, sectioned, and stained with
hematoxylin-eosin. The extent of cellular infiltration and
myocardial necrosis was blindly graded by two observers and
scored as follows: 0  no lesions; 1  lesions involving
25% of the myocardium; 2  lesions involving 25% to
50%; 3 lesions involving 50% to 75%; and 4 lesions
involving 75% to 100%. Scores assigned by the two observ-
ers were averaged.
Assay of cytokine levels in the heart. Cytokine levels in
the heart were measured as previously described (18).
Cytokine levels were measured with various enzyme-linked
immunosorbent assay kits manufactured by Genzyme Co.
(Cambridge, Massachusetts) for IL-6, IL-10, IL-12, and
tumor necrosis factor- (TNF-); BioSource International
(Camarillo, California) for IL-1-; and Endogen, Inc.
(Cambridge, Massachusetts) for IFN-. The sensitivity of
the kit is 5 pg/ml for IL-6; 15 pg/ml for IL-10, IL-12,
TNF-, and IFN-; and 7 pg/ml for IL-1-. Cytokine
levels are expressed as pg/mg of heart. The sensitivity of
IL-12 was 0.3 pg/mg of heart.
Assay of myocardial virus concentration. The myocardial
virus concentration was assayed by the FL (human amnion
cells)-plaque assay (19). The myocardial virus concentration
was expressed as log pfu/mg of heart. The sensitivity of this
method is 1.0 log pfu/mg of heart.
Statistical analysis. Survival was analyzed by the Kaplan-
Meier method. Statistical comparisons of plasma catechol-
amine levels, heart weight to body weight ratios (HW/BW,
an index of the severity of congestive heart failure), histo-
logic scores, and cytokine levels were performed by analysis
of variance with Bonferroni’s multiple comparisons correc-
tion. Measurements of myocardial virus concentration were
tested by the Kruskal-Wallis test. Data are expressed as the
mean value  SE. A p value 0.05 was considered
statistically significant.
RESULTS
Plasma epinephrine and norepinephrine levels. Plasma
epinephrine levels were significantly higher in the EMCV-
infected group than in the control group (6.22  1.44 vs.
0.11  0.04 ng/ml; n  5 in each; p  0.01). Likewise,
plasma norepinephrine levels were significantly higher in
the test group than in the control group (1.83  0.43 vs.
0.23  0.08 ng/ml; n  5 in each; p  0.01).
Dose-related effects of carvedilol. SURVIVAL RATE. The
14-day survival rate increased in a dose-dependent manner
and was significantly higher in the 10-mg/kg carvedilol
group (85.0%) than in the control group (45.0%; n  20 in
each; p  0.05) (Fig. 1a). The 14-day survival rate in the
3-mg/kg carvedilol group was 70.0% (14/20).
MYOCARDIAL HISTOLOGY AND HW/BW RATIO ON DAY
7. The HW/BW ratio and pathologic score decreased in a
dose-dependent manner and were significantly lower in the
low- and high-dose carvedilol group than in the control
group (Table 1).
CYTOKINE LEVELS IN THE HEART ON DAY 7. Figure 1b
illustrates the dose-dependent increase in IFN- levels,
reaching statistical significance in the comparison between
the high-dose carvedilol group and the control group (p 
0.05). On day 7, compared with an infected control value of
21.7  5.2 pg/mg of heart, carvedilol had increased IFN-
levels by 151.8  37.0% in the low-dose carvedilol group
and by 225.8  40.0% in the high-dose carvedilol group (n
 5 in each). No such effects were measured on IL-1-,
IL-6, or TNF- production (data not shown).
MYOCARDIAL VIRUS CONCENTRATION ON DAY 7. Figure 1c
shows that, on day 7, the myocardial virus concentration
decreased in a dose-dependent manner. Myocardial virus
concentration was 1.6  0.1 log pfu/mg heart in the
high-dose carvedilol group; 2.0  0.3 log pfu/mg heart in
the low-dose carvedilol group; and 2.5  0.2 log pfu/mg
Abbreviations and Acronyms
BW  body weight
EMCV  encephalomyocarditis virus
HW  heart weight
IFN  interferon
IL  interleukin
TNF  tumor necrosis factor
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heart in the control group (n  5 in each). The difference
between the high-dose treatment group and the control
group was statistically significant (p  0.05).
Comparison of the effects of carvedilol versus metoprolol
and propranolol. SURVIVAL RATE. The 14-day survival
rate was significantly higher in the carvedilol group (85%)
than in the control (40%), propranolol (50%), and meto-
prolol (35%) groups (n  20 in each; p  0.05) (Fig. 2a).
MYOCARDIAL HISTOLOGY AND HW/BW RATIO ON DAY 7.
The HW/BW ratio was significantly lower in the carvedilol
group than in the metoprolol, propranolol, and control
groups. The pathologic scores were significantly lower in the
carvedilol group than in the metoprolol and control groups.
The scores were lower in the propranolol treatment group,
and myocardial necrosis was significantly less in the pro-
pranolol group than in the control group (Table 2).
CYTOKINE LEVELS IN THE HEART ON DAY 7. Levels of
IFN- were significantly increased by carvedilol, unchanged
by metoprolol (p 0.05 vs. control and metoprolol groups),
and slightly increased by propranolol (Fig. 2b). Levels of
IL-12 were significantly increased by carvedilol (p  0.01
vs. control and metoprolol groups) and propranolol (p 
0.05 vs. control and metoprolol groups), but not by meto-
prolol (Fig. 2c). Levels of IL-10 were unchanged by these
three -blockers (data not shown). Compared with a
control value of 20.2  4.8 pg/mg of heart, IFN- levels
were 212.4 27.2% in the carvedilol group, 137.5 16.6%
in the propranolol group, and 106.0  17.4% in the
metoprolol group (n  5 in each). Levels of IL-12,
compared with a control value of 5.1  2.0 pg/mg of heart,
were 275.0 28.8%, 210.8 36.2%, and 115.8 39.1% in
the carvedilol, propranolol, and metoprolol, respectively (n
 5 in each).
MYOCARDIAL VIRUS CONCENTRATION ON DAY 7. Figure 2d
shows that, on day 7, the myocardial virus concentration of
1.5  0.3 log pfu/mg heart in the carvedilol group was
significantly lower (p 0.05) than the concentrations of 2.5
 0.2 log pfu/mg heart in the metoprolol group and 2.5 
0.2 log pfu/mg heart in the control group, whereas the
concentration in the propranolol group was only slightly
lower than that in the control group (2.3  0.2; n  5 in
each).
DISCUSSION
Carvedilol, cytokine production, and -antagonism. 2-
adrenergic agonists inhibit IL-12 and IFN- production in
vitro (6–8). We have studied the effects of -blockers and
epinephrine on the production of IFN- in human periph-
eral blood mononuclear cells stimulated by concanavalin A
(submitted manuscript). The production of IFN- was
significantly suppressed by epinephrine. Both carvedilol and
propranolol completely blocked these suppressive effects of
epinephrine. However, the selective 1-blocker metoprolol
had little effect. These results suggest that carvedilol blocked
the effects of epinephrine by blocking 2-adrenergic stim-
ulation. In this study, carvedilol improved survival, attenu-
ated myocardial lesions, and raised IL-12 and IFN- levels,
along with a decrease in the amount of myocardial virus.
Figure 1. Dose-related effects of carvedilol (mean  SE). (a) Survival rate
(n  20 in each group). Circles  control group; squares  3-mg/kg
carvedilol group; triangles  10-mg/kg carvedilol group. (b) Levels of
IFN- in the heart on day 7 (n  5 in each group). (c) Myocardial virus
concentration on day 7 (n  5 in each group). *p  0.05 versus control.
Carv-3  3 mg/kg carvedilol; Carv-10  10 mg/kg carvedilol.
Table 1. Dose-Dependent Effects of Carvedilol on HW/BW
and Myocardial Histology on Day 7
HW/BW (103)
Histologic Score
Necrosis Infiltration
Control 7.8  0.6 2.4  0.3 2.2  0.1
Carvedilol (3 mg/kg) 6.3  0.3* 1.6  0.2* 1.5  0.2*
Carvedilol (10 mg/kg) 6.0  0.2† 1.1  0.2† 1.2  0.1†
*p  0.05 vs. control. †p  0.01 vs. control. Data are presented as the mean value 
SE. Each group contained five mice.
HW/BW  heart weight to body weight ratio.
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Figure 2. Comparisons of the effects of carvedilol versus metoprolol and propranolol (mean  SE). (a) Survival rate (n  20 in each group). Circles 
control group; squares  30-mg/kg propranolol treatment group; diamonds  30-mg/kg metoprolol treatment group; triangles  10-mg/kg carvedilol
treatment group. *p  0.05 versus control, propranolol, and metoprolol groups. (b) Levels of IFN- in the heart on day 7 (n  5 in each group). *p 
0.05 versus control and metoprolol groups. (c) Levels of IL-12 in the heart on day 7 (n  5 in each group). *p  0.05 and #p  0.01 versus control and
metoprolol groups. (d) Myocardial virus concentration on day 7 (n  5 in each group). *p  0.05 versus control and metoprolol groups. Carv carvedilol;
Met  metoprolol; Prop  propranolol.
Table 2. Effects of Carvedilol, Metoprolol, and Propranolol on HW/BW and Myocardial
Histology on Day 7
HW/BW (103)
Histologic Score
Necrosis Infiltration
Control 7.8  0.6 2.2  0.1 2.0  0.2
Metoprolol (30 mg/kg) 8.3  0.6 2.4  0.6 2.3  0.5
Propranolol (30 mg/kg) 7.9  0.3 1.3  0.3* 1.6  0.2
Carvedilol (10 mg/kg) 6.2  0.7† 1.1  0.1† 1.1  0.2†
*p  0.05 vs. control and metoprolol groups. †p  0.01 vs. control and metoprolol groups. Data are presented as the mean value
 SE. Each group contained five mice.
HW/BW  heart weight to body weight ratio.
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Propranolol, to a lesser degree, also attenuated the extent of
myocardial lesions, raised IL-12 levels, and modestly in-
creased IFN-, although the increase was not statistically
significantly. Metoprolol, a selective 1-blocker, in contrast
to the nonselective -blockers carvedilol and propranolol,
had no effect in this model. These results suggest that
carvedilol exerts its therapeutic effects in part by an increase
in IL-12 and IFN- production by blocking 2-adrenergic
stimulation, and that endogenous catecholamines may reg-
ulate IL-12 and IFN- production in part by 2- instead of
1-adrenergic receptors in this model of viral myocarditis.
Carvedilol, cytokine production, and antioxidant prop-
erty. It is noteworthy that carvedilol caused a direct and
significant increase in concanavalin A–induced IFN- pro-
duction, an effect not observed with propranolol or meto-
prolol (submitted manuscript). In this study, propranolol
was less effective in increasing the production of IL-12 and
IFN-, despite its administration in doses equivalent to a
2-blocking potency three times that of carvedilol (17). This
suggests the participation of mechanisms other than
-adrenergic blockade. Carvedilol is an antioxidant and free
radical scavenger (14), which inhibits the production of
oxidized low-density lipoproteins (20) and the generation of
oxygen radicals by neutrophils (21). Oxidized low-density
lipoproteins are strong inhibitors of IL-12 and IFN-
production (22). In lymphocytes, lipid peroxide is produced
by stimulation of concanavalin A (23), and oxygen radicals
play an important pathogenetic role in this model (24).
Lipid peroxide and oxygen radicals suppress the production
of IFN- and IL-12, and carvedilol may inhibit the sup-
pressive effects of these oxidants. We have also studied the
effects of carvedilol on nonstimulated peripheral blood
mononuclear cells and found no IFN- production by
carvedilol, which may not be a direct inducer of IFN-.
Collectively, these results suggest that carvedilol increases
the production of IFN- and IL-12 by blocking 2-
receptors and antioxidant effects.
Carvedilol and 1-blocking effects. Besides being an an-
tioxidant, carvedilol has 1-adrenergic receptor blocking
properties (13). The effects of 1-adrenergic receptors on
IL-12 and IFN- production have not been described.
Until proven otherwise, the increase in IFN- production
cannot be attributed the 1-blocking property of carvedilol.
However, in view of our findings, in this same model in
which there was an attenuation of myocardial lesions on day
14 after EMCV inoculation by the 1-blocker bunazosin
(25), the 1-blocking property of carvedilol may have
contributed to the therapeutic effects observed in this study.
-blockers and large clinical trials. In recent randomized
clinical trials, carvedilol, metoprolol, and bisoprolol (a se-
lective 1-blocker) improved survival in patients with
chronic heart failure (9–11). The results of the metoprolol
and bisoprolol trials are not relevant to the observations
made in this study. There are several causes of dilated
cardiomyopathy, including viral infection, genetic factors,
and immunologic dysfunction (26). However, at present,
patients with dilated cardiomyopathy are not classified on
the basis of these mechanisms of disease. The results of our
experiments may not be directly relevant to the outcomes of
clinical trials. Carvedilol and nonselective -blockers with-
out intrinsic sympathomimetic activity may be more pro-
tective than selective 1-blockers in chronic heart failure
caused by viral myocarditis. In fact, in our earlier studies,
nonselective -blockers without intrinsic sympathomimetic
activity were more cardioprotective than selective 1-
blockers or nonselective -blockers with intrinsic sympa-
thomimetic activity (27) (unpublished data). In addition,
bucindolol, a nonselective -blocker with an 1-adrenergic
receptor blocking effect, did not confer a survival benefit in
patients with chronic heart failure (12). However, bucindo-
lol has an agonist-like binding property to the -receptors.
This property, including stimulation of 2-receptors, may
be one explanation for its neutral effects in clinical trials.
Conclusions. In this model of viral myocarditis, carvedilol,
compared with metoprolol and propranolol, conferred the
greatest therapeutic benefit by upregulating the production
of IL-12 and IFN- and by decreasing the virus load.
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